A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

  1. Rixe, O.
  2. Franco, S.X.
  3. Yardley, D.A.
  4. Johnston, S.R.
  5. Martin, M.
  6. Arun, B.K.
  7. Letrent, S.P.
  8. Rugo, H.S.
Revista:
Cancer Chemotherapy and Pharmacology

ISSN: 0344-5704

Any de publicació: 2009

Volum: 64

Número: 6

Pàgines: 1139-1148

Tipus: Article

DOI: 10.1007/S00280-009-0975-Z GOOGLE SCHOLAR
Font de les dades: Scopus